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Understanding  the  health  hazards  following  exposure  to food-borne  acrylamide,  especially  at  low  levels
typiﬁed by  human  diets,  is  an  ongoing  food  safety  issue.  We  recently  published  results  from  a  study  that
aimed  to understand  the  effects  of  acrylamide  short-term  exposure  at doses  known  to cause  tumors  in
rodents,  demonstrating  that  a number  of  key toxicological  end  points  were  altered  by acrylamide  expo-
sure.  Additionally,  we reported  that  at much  lower  doses  for 30 weeks  of  exposure,  dietary  acrylamide
was  ‘not  a  complete  carcinogen’  to the  colon  in  an  organ-speciﬁc  rodent  carcinogenesis  study  but  acted
as  a co-carcinogen  along  with  azoxymethane  (AOM,  a colon-speciﬁc  carcinogen).  Here, we present  toxi-
cological data  from  a sub-set  of  this  long-term  exposure  study  from  animals  that received  saline  (instead
of  AOM).  Brieﬂy,  male  F344  rats  were  randomized  to receive  acrylamide  at 0.5, 1.0  and 2.0  mg/kg  diet
(∼0.02,  0.04,  and 0.09 mg/kg  BW/day,  respectively)  or no  acrylamide  (control),  for  30 weeks;  all  rats
were  then  euthanized  and  their  tissues  harvested  and  processed  for toxicological  evaluation.  We  report
that at  the  doses  tested,  acrylamide  did  not  cause  any changes  in general  well-being,  body  weight  or  food
intake.  Similarly,  acrylamide  did  not  cause  any  biologically  relevant  change  in  parameters  associated  with
immunophenotyping,  serum  biochemistry  or hematology.  Histopathology  assessment  of tissues  showed
no changes  except  in the  testis,  where  non-speciﬁc  mild  lesions  were  observed  in all  the  groups,  inclusive
of  the  controls.  No  neuropathological  effects  of  acrylamide  were  observed  in  the  brain  and nerve  tissues.
Together,  these  results  suggest  that  acrylamide  administered  to rats  through  the diet at low  doses  for
30 weeks  did not  cause  any  toxicologically  relevant  changes.  Given  that  the  doses  of acrylamide  in  the
current  study  are  low  and  are  comparable  to  human  dietary  exposure,  this  null-effect  study  provides
data that  contribute  to the body  of scientiﬁc  evidence  relevant  to understanding  the health  effects  of
acrylamide.
Crown  Copyright  © 2016  Published  by  Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC. Introduction
Acrylamide, a known rodent carcinogen, was  discovered in
uman food by the Swedish National Food Agency (2002) [29]
nd since then acrylamide has been of concern in the context
f food safety. Acrylamide is found in a variety of popular foods
ncluding baby food, coffee, cereal, French fries, etc., at concentra-
ions that may  exceed 2 mg/kg of food [32,13,20]. At high doses,
∗ Corresponding author at: Regulatory Toxicology Research Division, Bureau
f  Chemical Safety, Food Directorate, Health Canada, C209 Frederick G. Banting
esearch Centre, Postal Locator 2202C, 251 Sir Frederick Banting Driveway, Ottawa,
1A 0K9, Ontario, Canada.
E-mail address: jayadev.raju@hc-sc.gc.ca (J. Raju).
ttp://dx.doi.org/10.1016/j.toxrep.2016.08.010
214-7500/Crown Copyright © 2016 Published by Elsevier Ireland Ltd. This is an open ac
y-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
including those known to induce rodent tumors (2-year cancer
bioassay), acrylamide has been shown to cause other non-cancer
toxic effects, including neurotoxicity and reproductive toxicity
[15,19,26]. The toxicokinetics and toxicodynamics of acrylamide
have been thoroughly studied [26]. Previous studies have exam-
ined the oral toxicity of acrylamide exposure via the three major
routes—food, drinking water and gavage using relevant rodent
models [19,5,6,17,11,3]. Acrylamide has been detected in multi-
ple tissues of orally-exposed rodents, including the brain, heart,
liver, lung, spleen, kidney, thymus, pancreas, and blood [1]; it
has been found in human breast milk and can cross the placen-
tal barrier [27]. Once inside the body acrylamide can form adducts
with hemoglobin, be conjugated with glutathione, or is oxidized by
CYP2E1 to form the more reactive epoxide glycidamide [8].
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Most rodent studies have focused on acrylamide at toxico-
ogically relevant high doses, which are known to cause tumors
19,5,6,17,11,3]. We  recently published two in vivo studies using
he azoxymethane (AOM)-induced rat colon carcinogenesis model,
emonstrating that food-borne acrylamide at high doses and
xposed for 8 weeks did not augment colon precancerous lesions
22]; and at low doses and exposed for 30 weeks was  ‘not a com-
lete carcinogen’ in the colon [21]. The latter study is one of the
ew that examined food-borne acrylamide exposure, at levels sim-
lar to those found in human foods in a long-term rodent model. In
he 30-week carcinogenesis study, the highest dose of acrylamide
2 mg/kg diet) increased the size of colon tumors in AOM-injected
ats and resulted in a higher occurrence of adenocarcinoma-type
esions, suggesting that acrylamide may  act as a co-carcinogen in
he colon and exacerbate the effects of AOM [21]. In the same paper,
e reported that dietary acrylamide did not aid in the progression
f established human colon tumor xenografts in the nude (nu/nu)
ouse model, and hence may  not play a role in colon tumor promo-
ion [21]. The aim of the present study was to understand if dietary
crylamide caused non-cancerous and non-linear toxic effects in
ale F344 rats exposed to low doses similar to human exposure lev-
ls. Brieﬂy, a set of rats randomized to four acrylamide dose groups
0, 0.5, 1.0, and 2.0 mg/kg diet) received saline (vehicle) instead of
OM, and were examined for pathology, hematology and clinical
iochemistry after 30-weeks of dietary exposure. We  report that
crylamide administered to rats through the diet at low doses for
0 weeks did not cause any toxicologically relevant changes.
. Methods
.1. Animal experimentation, husbandry and diets
The animal experimentation in this study was approved by the
ealth Canada Ottawa Animal Care Committee. The animals in
his study were a complete sub-set from our earlier carcinogenesis
tudy that served as a saline-treated control group [21]. All ani-
als were cared for according to the guidelines established by the
anadian Council on Animal Care. Brieﬂy, six-week-old male F344
ats were obtained from Charles River Laboratories (St. Constant,
uebec, Canada) and were pair housed with a 12 h:12 h light-dark
ycle, and with relative humidity and temperature controlled at
5% and 22 ◦C, respectively. The rats had ad libitum access to water
nd either basal diet (during the acclimatization phase) or experi-
ental diet (during the experimental phase). Diets were based on
he AIN-93G semi-synthetic formula modiﬁed to contain 7% corn
il [2] and obtained from Research Diets, Inc. (New Brunswick,
ew Jersey, USA). A week after acclimatization, rats were random-
zed (n = 8/group) to experimental diets containing acrylamide (Cat.
9099, purity ≥ 99%; Sigma-Aldrich Canada Co., Oakville, Ontario,
anada) at levels of 0.5, 1.0, or 2.0 mg/kg diet and the basal diet with
o acrylamide that served as the control. Acrylamide was  added to
he powdered diets using a Hobart mixer and pelleted in our diet
reparation facility. During pelleting, the temperature was  main-
ained below 35 ◦C to avoid any additional acrylamide formation
uring the processing of the diets. Diets were stored at 4 ◦C, in
he dark, until use. The homogeneity, stability and background lev-
ls of acrylamide in rodent diets have been earlier reported by the
ational Toxicology Program (NTP; 2012) [19], where the levels of
crylamide analyzed by capillary gas chromatography with ﬂame
onization detection, were found to be below the Limit of Quantita-
ion in all their control diets. Our diet preparations were similar to
hat of the rodent diets utilized in the NTP studies [19], and based on
ur diet preparation conditions, any background acrylamide levels
n our diets are expected to be negligible and below the Limit of
uantitation.orts 3 (2016) 673–678
Food consumption by the rats was measured biweekly and diets
were replaced weekly. The health and general behaviour of the
rats were monitored daily and body weights were measured twice
a week. After the 30-week experimental period, rats were killed
by exsanguination under isoﬂurane anesthesia; organs were dis-
sected and their wet weights recorded. Collected organs included
the brain, tibial nerve, liver, kidney, pancreas, epididymis, heart,
mesenteric lymph node, adrenal glands, colon, small intestine, thy-
mus, spleen, prostate, lungs, and testes. The organs were ﬁxed in
neutral buffered formalin, except the testes which were ﬁxed in
modiﬁed Bouin’s solution, for pathological examination. Blood to
be used for serum biochemistry was collected in BD Vacutainer
SSTTM blood collection tubes (Becton-Dickinson, Franklin Lakes,
New Jersey, USA) and allowed to clot at room temperature. Serum
was separated by centrifugation at 700 × g and stored at −80 ◦C
until analysis. Blood to be used for hematology and immunophe-
notyping was  collected in BD Vacutainer K2-EDTA blood collection
tubes.
2.2. Histopathology
The tissue sections were assigned to coded ID numbers to ensure
the pathologist (D.C.) was  blinded to treatment groups. Microscopic
examinations were conducted on formalin-ﬁxed (modiﬁed Bouin’s
solution for testes), parafﬁn-embedded 5-m sections of the lung,
liver, kidney, pancreas, epididymis, heart, mesenteric lymph nodes,
colon, small intestine, adrenal gland, thymus, spleen, prostate and
testis stained with hematoxylin and eosin (H&E); the brain and tib-
ial nerve sections were stained with hematoxylin-phloxine-saffron
(HPS).
2.3. Hematology and serum clinical biochemistry
An AcT5 Diff CP analyzer (Beckman Coulter Canada, Inc., Mis-
sissauga, Ontario, Canada) was used for the plasma analysis of
the following hematological parameters: red blood cell count,
hematocrit, hemoglobin (HGB), mean corpuscular volume, mean
corpuscular hemoglobin, mean corpuscular hemoglobin concen-
tration, red blood cell distribution width, platelet counts, mean
platelet volume, and white blood cell counts (total and differen-
tiated). A Pentra 400 (HORIBA ABX Inc., Irvine, California, USA)
was used to measure serum clinical biochemistry parameters
including amylase, albumin, alkaline phosphatase (ALP), alanine
transaminase (ALT), aspartate transaminase (AST), calcium, carbon
dioxide (CO2), chloride, cholesterol, including high and low density
lipoprotein cholesterol, creatinine, creatine kinase (CK), glucose,
iron, lipase, magnesium, phosphorous, potassium, sodium, sodium:
potassium ratio, total protein, triglycerides, and blood urea nitro-
gen (BUN).
2.4. Serum testosterone
Serum testosterone (T) assays were conducted on all males in
duplicate using a commercial ELISA kit, (IBL America, Minneapolis,
Minnesota, USA). The cross reactivity of dihydrotestosterone (DHT)
is quoted as 0.8%. The inter-and intra-assay coefﬁcients of variation
(CV%) for serum T were 3.3% (n = 3) and 7.1% (n = 3), respec-
tively. Intra- and inter-assay coefﬁcients of variations (CV%) for
ELISA assays were experimentally derived from the data provided
with the PolarStar Optima plate reader (BMG Labtech, Ortenberg,
Germany).2.5. Immunophenotyping
Leukocytes in whole blood and the thymus were characterized.
Brieﬂy, red blood cells were lysed in the whole blood samples. Thy-
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us  tissues were gently crushed in a 70 m nylon cell strainer (BD
alcon, Bedford, MA,  USA) and rinsed into a 50 mL  tube in Dul-
ecco’s phosphate buffered saline (Gibco/Invitrogen, Grand Island,
ew York, USA) to create thymocyte suspensions. Thymocyte and
lood suspensions were standardized to ensure equal cell con-
entrations per mL  of suspension. Mouse anti-rat monoclonal
ntibodies from BD Biosciences (Mississauga, Ontario, Canada)
ere used to characterize T lymphocytes, helper T cells, cytotoxic T
ells, B cells, and natural killer cells in the whole blood and thymus.
onocytes were also measured in whole blood. Suspensions were
ixed with respective antibodies and were ﬁxed with 2% formalde-
yde solution. Lymphocyte subset analyses were conducted by ﬂow
ytometry on a BD FACSCaliber System (BD Biosciences, Missis-
auga, Ontario, Canada).
.6. Statistical analysis
Serum testosterone levels were compared using ANOVA and a
ost-test for linear regression using Prism Version 6.01 (Graph-
ad Software, Inc., La Jolla, California, USA). All other data were
nalyzed using ANOVA using SigmaStat(R) 3.1 software (Systat Soft-
are Inc., Point Richmond, California, USA). P < 0.05 was  considered
igniﬁcant for all statistical tests.
. Results and discussion
Acrylamide, a known rodent carcinogen, genotoxin and neuro-
oxin, is formed as a consequence of a Maillard reaction between
he carbonyl group of reducing sugars and asparagine in a range
f human foods processed at high temperature [28]. Acrylamide
s classiﬁed as a ‘probable human carcinogen—Class 2A’ [15], and
here is ongoing research to understand its health effects for haz-
rd identiﬁcation and regulatory risk assessments (reviewed in
10]). Earlier, we demonstrated that food-borne acrylamide at
evels comparable to those found in human foods was  ‘not an
ndependent carcinogen to the colon’ in male F344 rats using the
OM-induced colon carcinogenesis model [21]. In that study, the
arcinogen-treated rats were dosed with 0.5, 1.0, and 2.0 mg/kg
iet for 30 weeks and the average intake of acrylamide was calcu-
ated as 0.018, 0.036 and 0.072 mg/kg BW/day, respectively [21].
isk assessments typically examine the effects of high doses of
hemicals to determine lowest/no observed adverse effect levels
L/NOAELs). Emphasizing the importance of low dose effects in tox-
cology [4], addressed the “low-dose hypothesis” which postulates
hat low doses of chemicals can have effects with nonmonotonic
ose-response curves leading to non-linear responses that would
ot necessarily be predicted from their effects at high doses. Here,
e present data from the previous study [21], pertaining to our
ematological, clinical biochemistry and pathological ﬁndings from
 sub-set of rats that were exposed to low-dose dietary acrylamide
ut not AOM, the carcinogen.
able 1
ean body weight (g) of male F344 rats in a 30-week feeding study of acrylamidea.
Dose Body weight (g) (Relat
Week 1 Week 5 Week 10 W
Control 186.4 ± 8.0 279.2 ± 9.1 351.5 ± 9.9 3
0.5  mg/kg 211.0 ± 3.9
(113)
307.7 ± 4.3
(110)
380.8 ± 5.7
(108)
4
(
1.0  mg/kg 197.8 ± 4.6
(106)
290.0 ± 5.5
(104)
363.4 ± 7.3
(103)
4
(
2.0  mg/kg 201.1 ± 4.8
(108)
297.7 ± 5.3
(106)
365.2 ± 5.4
(104)
4
(
a Weights expressed as mean ± standard error of the mean.rts 3 (2016) 673–678 675
In the current study, none of the rats exhibited signs of discom-
fort or changes in their general behaviour that could be associated
with acrylamide-toxicity. Prior to the commencement of the treat-
ments, the body weight of rats ranged from 113 to 190 g and the
weekly measured body weights did not differ between dietary
groups at any given time point (Table 1). At the end of the 30-week
exposure (at necropsy), there were no acrylamide-related change
in body weights. It should be noted that in the study reported by
[19], the lowest dose of acrylamide at a dose of 0.33 mg/kg BW/day
caused no change in body weight at 28 and 32 weeks. Relative
wet weights of the thymus, heart, liver, spleen, pancreas, adrenal
glands, testis and epididymis were calculated as g per 100 g BW
and were not signiﬁcantly different by comparison to the con-
trol (Table 2). Food consumption was  calculated as g of food per
kg BW per day (Table 3), with no signiﬁcant difference observed
between the acrylamide-treated groups and the control. Based on
the calculated food consumption, the mean overall intake of acry-
lamide in the 0.5, 1.0 and 2.0 mg/kg diet dose groups was calculated
as 0.022 ± 0.001, 0.044 ± 0.002, and 0.088 ± 0.004 mg/kg BW/day,
respectively. We  employed allometric scaling to assess the human
equivalent dose (HED) of acrylamide from the dietary exposure
the rats received, by using the exponent 0.67 for body surface area
[31,24]. We  calculated the HED as ∼0.003, 0.007 or 0.014 mg/kg/BW
for rats exposed to acrylamide at 0.5, 1.0 or 2.0 mg/kg diet. These
levels are congruent with the actual upper human exposure levels
of 0.003–0.0034 mg/kg BW/day (90–95th percentile of high level
human consumers) detected by different food regulatory agencies
[33,14,9,34]. In addition, based on national and regional estimates,
a dietary exposure to acrylamide of 0.001 mg/kg BW per day was
representative of the mean for the general population (including
children), and a dietary exposure of 0.004 mg/kg BW per day rep-
resented consumers with a high dietary exposure [16].
H&E stained sections of liver, kidney, pancreas, epididymis,
heart, mesenteric lymph node, adrenal glands, thymus, spleen,
prostate and lung were examined and no neoplastic or non-
neoplastic lesions were found in either the acrylamide-treated
or control rats. Acrylamide-induced testicular toxicity has been
widely studied; acrylamide, at toxicologically relevant oral doses
(2.5–50 mg/kg BW/day) for 14 days, caused signiﬁcant effects on
Leydig and germ cells in the testes of male F344 rats [7]. In the cur-
rent study, we did not observe such pathological changes; however,
in the testis, mild degeneration (vacuolation) of the seminiferous
epithelia with single or few atrophied tubules were noted in all the
rats (including the controls) with no evidence for an acrylamide-
related effect. These non-speciﬁc mild testicular tubule atrophies
are likely related to the F344 strain and age (>36 weeks) as observed
at necropsy by [12]. Additionally, there is historical evidence of
mild testicular tubule atrophies in control male F344 rats (27%) as
reported in the 2-year drinking water study of acrylamide by the
[19]. It should be noted that in a previous oral exposure study, acry-
lamide at a high dose of 40 ppm (equivalent to 4.4 mg/kg BW/day)
administered for 12 weeks caused testicular toxicity, but no effects
ive percent in comparison to Control)
eek 15 Week 20 Week 25 Week 30
95.4 ± 9.5 423.0 ± 8.6 447.4 ± 8.7 458.1 ± 10.7
20.7 ± 6.1
106)
449.7 ± 6.2
(106)
473.5 ± 6.5
(106)
486.6 ± 8.9
(106)
07.4 ± 8.6
103)
434.8 ± 10.2
(103)
459.2 ± 10.3
(103)
466.7 ± 10.4
(102)
05.0 ± 5.7
102)
435.7 ± 5.9
(103)
455.1 ± 5.3
(102)
473.3 ± 6.2
(103)
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Table 2
Mean organ wet  weightsa (g/100 g BW)  of male F344 rats in a 30-week feeding study of acrylamide.
Organ weights (g/100 g BW)
Control 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg
Thymus 0.0338 ± 0.0024 0.0361 ± 0.0016 0.0346 ± 0.0022 0.0400 ± 0.0031
Heart  0.2564 ± 0.0060 0.2495 ± 0.0053 0.2621 ± 0.0043 0.2636 ± 0.0031
Liver  3.1436 ± 0.0356 3.1858 ± 0.0549 3.1278 ± 0.0301 3.0849 ± 0.0636
Spleen  0.1733 ± 0.0027 0.1822 ± 0.0041 0.1798 ± 0.0031 0.1809 ± 0.0022
Pancreas 0.1989 ± 0.0077 0.2098 ± 0.0056 0.2205 ± 0.0087 0.2231 ± 0.0090
AGb 0.0102 ± 0.0003 0.0099 ± 0.0003 0.0102 ± 0.0003 0.0103 ± 0.0002
Prostate 0.0844 ± 0.0071 0.0692 ± 0.0037 0.0643 ± 0.0050 0.0698 ± 0.0055
Testis  0.7442 ± 0.0177 0.7103 ± 0.0373 0.7937 ± 0.0257 0.7799 ± 0.0303
Epididymis 0.2028 ± 0.0064 0.1894 ± 0.0121 0.2097 ± 0.0029 0.2001 ± 0.0071
a Weights expressed as mean wet weights per 100 g body weight ± standard error of the mean. bAG = adrenal glands.
Table 3
Food and acrylamide consumption of male F344 rats in a 30-week feeding study of acrylamide.
Dose Mean food consumptiona (g/kg BW/day) (Relative percent in comparison to Control)
Week 1 Week 5 Week 10 Week 15 Week 20 Week 25 Week 30
Control 81.1 ± 2.5 55.8 ± 1.3 46.7 ± 1.3 41.2 ± 1.1 39.5 ± 0.7 37.9 ± 0.6 34.5 ± 0.6
0.5  mg/kg 78.9 ± 1.0
(97)
53.9 ± 0.7
(97)
44.6 ± 0.9
(95)
39.4 ± 0.6
(96)
39.4 ± 0.7
(100)
35.9 ± 0.5
(95)
33.9 ± 0.4
(98)
1.0  mg/kg 78.7 ± 1.3
(97)
53.5 ± 0.7
(96)
44.6 ± 0.6
(95)
39.7 ± 0.6
(96)
40.0 ± 1.2
(101)
36.3 ± 0.6
(96)
33.6 ± 0.5
(97)
2.0  mg/kg 79.7 ± 1.3
(98)
54.9 ± 0.9
(98)
43.9 ± 0.9
(94)
40.0 ± 0.5
(97)
39.8 ± 0.5
(101)
36.9 ± 0.4
(97)
33.9 ± 0.4
(98)
Dose  Mean acrylamide consumption (g/kg BW/day)
Week 1 Week 5 Week 10 Week 15 Week 20 Week 25 Week 30
Control 0 0 0 0 0 0 0
0.5  mg/kg 39.5 ± 0.5 26.9 ± 0.4 22.3 ± 0.5 19.7 ± 0.3 19.7 ± 0.4 17.9 ± 0.2 17.0 ± 0.2
1.0  mg/kg 78.7 ± 1.3 53.5 ± 0.7 44.6 ± 0.6 39.7 ± 0.6 40.0 ± 1.2 36.3 ± 0.6 33.6 ± 0.5
2.0  mg/kg 159.4 ± 2.5 109.7 ± 1.8 87.9 ± 1.9 79.9 ± 1.1 79.6 ± 1.1 73.9 ± 0.8 67.8 ± 0.8
a Food consumption expressed as mean food consumed per kg body weight of rat per day ± standard error of the mean. Food was measured by cage, divided by number
of  days since previous measurement, divided by 2 rats per cage, divided by mean body weight of the 2 rats.
Table 4
Serum clinical biochemistry of male rats in a 30-week feeding study of acrylamide.
Control 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg
Albumin (g/L) 32.0 ± 1.0 32.8 ± 0.7 32.4 ± 0.7 32.4 ± 0.7
ALT  (U/L) 59.5 ± 6.6 55.1 ± 3.9 76.3 ± 25.9 58.5 ± 4.6
ALP  (U/L) 125.3 ± 8.3 120.6 ± 3.4 149.2 ± 18.7 126.9 ± 5.7
Amylase (U/L) 3112 ± 63 3163 ± 89 3034 ± 109 2931 ± 59
AST  (U/L) 81.3 ± 4.7 79.3 ± 5.0 80.8 ± 9.2 77.4 ± 4.2
BUN  (mmol/L) 6.3 ± 0.3 6.3 ± 0.1 5.9 ± 0.2 6.1 ± 0.2
Calcium (mmol/L) 2.95 ± 0.11 3.00 ± 0.08 2.99 ± 0.08 2.99 ± 0.09
Chloride (mmol/L) 98.6 ± 0.8 98.4 ± 0.9 98.5 ± 0.9 98.6 ± 0.9
Cholesterol (mmol/L) 3.1 ± 0.1 3.3 ± 0.1 3.1 ± 0.1 3.3 ± 0.1
HDL  (mmol/L) 0.86 ± 0.05 0.88 ± 0.03 0.83 ± 0.03 0.87 ± 0.04
LDL  (mmol/L) 0.29 ± 0.01 0.31 ± 0.02 0.30 ± 0.01 0.30 ± 0.02
CK  (U/L) 448.7 ± 28.0 388.2 ± 30.1 340.1 ± 31.6 309.2 ± 38.0*
CO2 (mmol/L) 29.5 ± 0.3 29.7 ± 0.2 30.4 ± 0.2 31.0 ± 0.3*
Creatinine (mmol/L) 30 ± 3 30 ± 3 32 ± 3 29 ± 2
Glucose (mmol/L) 8.2 ± 0.5 8.2 ± 0.4 9.2 ± 0.6 9.6 ± 0.6
Iron  (mol/L) 33.55 ± 0.72 33.01 ± 0.33 31.40 ± 0.71 31.12 ± 0.92
Lipase (U/L) 6.8 ± 0.6 6.7 ± 0.8 6.7 ± 0.9 8.2 ± 0.8
Magnesium (mmol/L) 0.59 ± 0.03 0.61 ± 0.02 0.61 ± 0.01 0.62 ± 0.02
Phosphorus (mmol/L) 1.8 ± 0.1 2.0 ± 0.1 1.9 ± 0.1 2.0 ± 0.1
Potassium (mmol/L) 4.1 ± 0.1 4.3 ± 0.1 4.2 ± 0.1 4.1 ± 0.1
Sodium (mmol/L) 140.8 ± 1.0 140.9 ± 0.8 140.7 ± 0.7 140.8 ± 0.8
Total  Protein (g/L) 68.6 ± 1.7 70.2 ± 0.6 68.8 ± 0.2 69.5 ± 0.9
Triglycerides (mmol/L) 3.17 ± 0.17 3.65 ± 0.28 3.61 ± 0.25 4.05 ± 0.27
Testosterone (ng/mL) 1.791 ± 0.325 2.019 ± 0.205 2.390 ± 0.227 2.534 ± 0.417
A trol (
A tein, L
w
r
l
gn asterisk (*) denotes value that is signiﬁcantly different (p < 0.05) from the con
ST—aspartate transaminase, BUN—blood urea nitrogen, HDL—high density lipoproere observed at either 10 or 20 ppm [30]. Supporting our data
elated to the testes, we found no changes in serum testosterone
evels between the control and any of the acrylamide-treated
roups (Table 4), suggesting no male hormone-speciﬁc testicularno acrylamide exposure). ALT—alanine transaminase, ALP—alkaline phosphatase,
DL—low density lipoprotein, CK—creatine kinase, CO2—carbon dioxide.toxicity at low dose exposure. Similarly [7], reported changes in
serum testosterone in male F344 rats exposed at a dose of 10 mg/kg
BW/day acrylamide or greater, with no changes in animals tested
at a lower dose of 2.5 mg/kg BW/day. To assess any neurological
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Table  5
Hematology of male F344 rats in a 30-week feeding study of acrylamide.
Control 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg
WBC  4.2 ± 0.3 4.6 ± 0.2 4.3 ± 0.1 4.1 ± 0.1
RBC  8.57 ± 0.06 8.78 ± 0.08 8.70 ± 0.05 8.67 ± 0.06
HGB  142 ± 1 146 ± 1* 144 ± 1 145 ± 1*
HCT  0.414 ± 0.003 0.424 ± 0.003 0.421 ± 0.002 0.422 ± 0.002
MCV  48 ± 0 48 ± 0 48 ± 0 49 ± 0
MCH  16.6 ± 0.1 16.6 ± 0.1 16.6 ± 0.1 16.7 ± 0.1
MCHC  343 ± 1 344 ± 1 343 ± 1 345 ± 1
RDW  12.9 ± 0.1 12.7 ± 0.1 12.6 ± 0.1 12.7 ± 0.2
PLT  537 ± 8 540 ± 8 532 ± 8 517 ± 12
MPV  7.2 ± 0.1 7.1 ± 0.1 7.1 ± 0.1 7.2 ± 0.2
NE%  34.1 ± 1.4 35.8 ± 1.5 33.2 ± 1.1 31.1 ± 1.8
LY%  59.6 ± 1.4 58.2 ± 1.7 60.5 ± 0.9 62.2 ± 1.7
MO%  3.5 ± 0.3 3.1 ± 0.2 3.3 ± 0.4 3.5 ± 0.4
EO%  2.5 ± 0.1 2.5 ± 0.2 2.8 ± 0.2 2.9 ± 0.2
BA%  0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0
NE#  1.43 ± 0.13 1.66 ± 0.14 1.44 ± 0.06 1.27 ± 0.09
LY#  2.50 ± 0.17 2.65 ± 0.10 2.62 ± 0.08 2.53 ± 0.07
MO#  0.15 ± 0.02 0.14 ± 0.02 0.14 ± 0.02 0.14 ± 0.02
EO#  0.11 ± 0.01 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.01
BA#  0.01 0.00 0.02 0.00 0.01 0.00 0.02 0.00
An asterisk (*) denoted those that are signiﬁcantly different (p < 0.05) from controls.
WBC—white blood cell, RBC − red blood cell, HGB—hemoglobin, HCT—hematocrit, MCV—mean corpuscular volume, MCH—mean corpuscular hemoglobin, MCHC—mean
corpuscular hemoglobin concentration, RDW—red blood cell distribution width, PLT—platelet count, MPV—mean platelet volume, NE—Neutrophils, LY—Lymphocytes,
MO—Monocytes, EO —Eosinophils, BA—Basophils.
Table 6
Leukocyte characterization of the thymus and whole blood of male rats in a 30-week feed study of acrylamide.
Control 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg
Whole Blood
T lymphocytesa
CD3+
48.3 ± 2.4 50.2 ± 2.7 53.4 ± 2.4 52.2 ± 3.8
Helper  T cellsa
CD3+/CD4+
30.6 ± 1.9 30.9 ± 1.8 32.7 ± 1.8 31.4 ± 2.6
Cytotoxic T cellsa
CD3+/CD8a+
18.3 ± 0.9 20.2 ± 1.3 21.7 ± 0.8 21.8 ± 1.5
B  cellsa
CD45RA+/CD3-
13.9 ± 1.8 14.1 ± 1.9 15.7 ± 2.0 16.2 ± 1.5
NKb cellsa
CD161a+ (high)/CD3-CD161a+ (med)/CD3-
2.4 ± 0.2
30.9 ± 2.8
2.9 ± 0.3
29.8 ± 4.3
3.5 ± 0.5
24.7 ± 4.7
2.8 ± 0.2
26.0 ± 5.2
Monocytesa
CD4+/CD3-
7.2 ± 0.9 6.1 ± 0.3 7.0 ± 0.4 7.2 ± 0.5
Thymus
Immature
thymocytesa
CD4-/CD8-
4.03 ± 0.29 3.92 ± 0.21 3.81 ± 0.20 4.15 ± 0.22
Immature
thymocytesa
CD4+/CD8+
84.32 ± 0.57 84.32 ± 0.52 84.45 ± 0.33 84.37 ± 0.49
Helper  T cellsa
CD4+/CD8-
8.60 ±0.41 8.69 ± 0.30 8.61 ± 0.21 8.59 ± 0.39
Cytotoxic T cellsa 3.07 ± 0.28 3.08 ± 0.28 3.11 ± 0.26 2.88 ± 0.13
c
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(CD4-/CD8+
a % leukocyte (CD45 + ) cells.
b Natural Killer.
hanges related to acrylamide exposure, cross-sections of the brain,
t the level of the optic chiasm and another including brainstem and
erebellum, were examined and no lesions were found in any of the
ietary groups.
A battery of tests was performed to determine the levels of bio-
hemical parameters, some of which are used to assess liver and
idney function/damage (Table 4). Serum levels of the enzymes
LT, AST and ALP were not affected by acrylamide treatment. Total
rotein was unaffected between dietary groups, with no concomi-
ant change in BUN values and creatinine. There was no change
bserved in the activity of serum CK in the 0.5 and 1.0 mg  acry-
amide/kg diet groups. However, a decrease (P < 0.05) was observed
n the 2.0 mg  acrylamide/kg diet group by comparison to the control
Table 4). This value still fell within the range considered biologi-cally normal and thus is unlikely to indicate a toxic effect. Moreover,
the BUN value, which is often taken in conjunction with the CK
values to indicate renal dysfunction, was  unaltered across dietary
groups. Acrylamide is known to bind to CK leading to CK inacti-
vation [25]; this may  be a contributing factor to the decrease in
serum CK activity that we have observed in rats from the 2.0 mg
acrylamide/kg diet group.
An increase (P < 0.05) in serum CO2 was observed in the high-
est tested acrylamide dose group of 2.0 mg/kg diet in comparison
to the control; no changes were seen in the other two acrylamide
dose groups (Table 4). The CO2 levels in all the groups fell within
the healthy range, indicating that the increase we  observed in the
2.0 mg  acrylamide/kg diet was not biologically relevant. Previously,
we reported that acrylamide administered for a short duration (10
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gov/downloads/Food/FoodborneIllnessContaminants/UCM197239.pdf.
[34] W.W.  Wong, S.W. Chung, C.H. Lam, Y.Y. Ho, Y. Xiao, Dietary exposure of hong
kong adults to acrylamide: results of the ﬁrst Hong Kong total diet study,78 J. Raju et al. / Toxicolog
eeks) up to a dose of 50 mg/kg diet did not affect serum CO2 levels
n F344 rats [23].
In the hematological panel of tests (Table 5) and the leukocyte
haracterization (Table 6), we observed no changes in any param-
ters between control and acrylamide-treated groups, with the
xception of HGB. An increase (P < 0.05) in HGB was  observed in
he 0.5 and 2.0 mg  acrylamide/kg diet groups in comparison to the
ontrol. There was no dose-dependent pattern in the HGB levels,
nd no difference was observed between the 1.0 mg  acrylamide/kg
iet group and the controls (Table 5). The HGB values fell within
he healthy range, and thus the increase in the upper and lower
ose groups do not indicate toxicity. Other rodent studies reported
hat acrylamide in fact decreased hemoglobin levels [18,23], and
he decrease was accompanied by other hematological changes,
ncluding decreased hematocrit and mean corpuscular hemoglobin
23] and increased bilirubin [18]. Such changes in associated hema-
ological parameters were not observed in this study.
. Conclusion
After a 30-week exposure, no toxicologically relevant changes
ere noted in male F344 rats fed acrylamide at levels of 0.5, 1.0, and
.0 mg/kg diet, conﬁrming the absence of any possible non-linear
esponses. These low dose levels were chosen as they are compa-
able to those found in a variety of foods commonly consumed by
umans. Given that the acrylamide doses and exposure (diet and
uration) strategies adopted in the current rodent study are com-
arable to human dietary exposure, the ‘no-effect’ data generated
y this study will be useful in conjunction with other literature, and
ill contribute to the body of scientiﬁc evidence used to inform the
isk assessment of dietary exposure to acrylamide.
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